Siegfried Holding AG/Fr. SFZN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Siegfried Holding AG
Siegfried Holding AG operates in the pharmaceuticals and healthcare industry, specializing in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company provides comprehensive contract development and manufacturing services to the pharmaceutical industry, including product development, manufacturing, and packaging. Founded in 1873, Siegfried has a long-established history and is headquartered in Zofingen, Switzerland. Its strategic positioning lies in its global manufacturing network, with facilities across Europe, North America, and Asia, which allows it to serve a diverse international client base effectively. The company's competitive strength is enhanced by its integrated service offerings and commitment to quality and innovation in pharmaceutical production.
- Ticker
- Fr. SFZN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 4,454
- Headquarters
- Zofingen, Switzerland
- Website
- www.siegfried.ch
SFZN Metrics
BasicAdvanced
CHF 3.1B
18.35
CHF 3.90
0.81
CHF 0.40
0.56%
Price and volume
Market cap
CHF 3.1B
Beta
0.81
52-week high
CHF 101.60
52-week low
CHF 65.05
Average daily volume
101K
Dividend rate
CHF 0.40
Financial strength
Current ratio
3.453
Quick ratio
1.359
Long term debt to equity
0.931
Total debt to equity
0.931
Dividend payout ratio (TTM)
10.23%
Interest coverage (TTM)
24.15%
Profitability
EBITDA (TTM)
316.528
Gross margin (TTM)
26.97%
Net profit margin (TTM)
12.77%
Operating margin (TTM)
16.71%
Effective tax rate (TTM)
19.29%
Revenue per employee (TTM)
CHF 300,000
Management effectiveness
Return on assets (TTM)
6.38%
Return on equity (TTM)
16.96%
Valuation
Price to earnings (TTM)
18.348
Price to revenue (TTM)
2.343
Price to book
3.13
Price to tangible book (TTM)
3.34
Price to free cash flow (TTM)
-109.373
Free cash flow yield (TTM)
-0.91%
Free cash flow per share (TTM)
-0.654
Dividend yield (TTM)
0.56%
Growth
Revenue change (TTM)
3.64%
Earnings per share change (TTM)
11.22%
3-year revenue growth (CAGR)
2.38%
10-year revenue growth (CAGR)
7.79%
3-year earnings per share growth (CAGR)
3.84%
10-year earnings per share growth (CAGR)
16.69%
3-year dividend per share growth (CAGR)
5.57%
10-year dividend per share growth (CAGR)
8.31%
What the Analysts think about SFZN
Analyst ratings (Buy, Hold, Sell) for Siegfried Holding AG stock.
Analyst projections of the future price of Siegfried Holding AG stock.
Bulls say / Bears say
First-half sales rose 4.8% in local currencies and core EBITDA margin improved to 22.4%. Siegfried kept its 2026 targets of high-single-digit local-currency growth and a core EBITDA margin above 23%. (Siegfried)
The acquisition of three US and Australian sites expands Siegfried’s development-to-commercial manufacturing network, and the company reported strong customer interest in the added US capacity. Successful integration could give it more room to win customer projects and grow its US business. (Siegfried)
Siegfried has added 100 m³ of reactor capacity at its Minden site and secured Swissmedic approval for GMP viral-vector manufacturing at DINAMIQS. These upgrades broaden its ability to serve customers in complex APIs and genomic medicines. (Siegfried)
Operating cash flow fell to CHF93.7 million from CHF149.6 million a year earlier, while net debt rose to 2.3 times core EBITDA after the acquisition. Weaker cash conversion and higher leverage leave less financial room until working capital improves and debt is repaid. (Investing.com)
Drug Products sales grew only 1.5% in local currencies in the first half, and analysts said the full-year target depends on a stronger second half. That back-loaded profile leaves results more exposed to production delays or missed delivery milestones. (Siegfried, Investing.com)
The acquired sites and new US capacity still need to be converted into customer production: Siegfried expects first revenue from new exclusive business in 2027, with a gradual ramp from 2028. Any delay in transfers or customer uptake could postpone the acquisition’s payoff. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
SFZN Financial Performance
Revenues and expenses
SFZN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SFZN
AllUSDEURGBP
Fund name | Fund size | Fr. SFZN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.34% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.34% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.34% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.21% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.